Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin (AMPLITUDE-D)
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion criteria:
- Participant must be greater than or equal to (>=) 18 years of age at the time of signing the informed consent.
- Participants with T2DM.
- Diabetes diagnosed at least 1 year before screening.
- Participants on stable dose of at least 1500 milligram per day (mg/day) of metformin, or tolerated maximum dose, or as per country regulation if less, for at least 3 months prior to screening.
- HbA1c between 7.0 percent (%) and 10.0% (inclusive) measured by the central laboratory at screening.
Exclusion criteria:
- Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.
- Clinically relevant history of gastrointestinal (GI) disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease requiring medical treatment within 6 months prior to screening or history of surgery affecting gastric emptying.
- History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy had been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
- Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g., multiple endocrine neoplasia syndromes).
- Body weight change of greater than or equal to (>=) 5 kilogram within the last 3 months prior to screening.
- Systolic blood pressure greater than (>)180 millimeter of mercury (mmHg) and/or diastolic blood pressure >100 mmHg at randomization.
- Severe renal disease as defined by estimated glomerular filtration rate (eGFR), by Modification of Diet in Renal Disease (MDRD)] of less than (<)30 mL/min/1.73 m^2.
- Laboratory findings at the screening visit:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 * upper limit of normal (ULN) or total bilirubin >1.5 * ULN (except in case of documented Gilbert's syndrome);
- Amylase and/or lipase: >3 * ULN;
- Calcitonin >=5.9 picomoles per liter (pmol/L) (20 picograms per milliliter).
- Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to screening, or planned during study period.
- Pregnant (confirmed by serum pregnancy test at screening) or breast-feeding women.
- Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control or who are unwilling to be tested for pregnancy during the study period and for at least 5 weeks after the last dose of study intervention.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 8400038
- Investigational Site Number 8400035
- Investigational Site Number 8400005
- Investigational Site Number 8400054
- Investigational Site Number 8400057
- Investigational Site Number 8400009
- Investigational Site Number 8400007
- Investigational Site Number 8400045
- Investigational Site Number 8400040
- Investigational Site Number 8400026
- Investigational Site Number 8400050
- Investigational Site Number 8400055
- Investigational Site Number 8400041
- Investigational Site Number 8400025
- Investigational Site Number 8400060
- Investigational Site Number 8400059
- Investigational Site Number 8400044
- Investigational Site Number 8400061
- Investigational Site Number 8400001
- Investigational Site Number 8400039
- Investigational Site Number 8400028
- Investigational Site Number 8400036
- Investigational Site Number 8400013
- Investigational Site Number 8400014
- Investigational Site Number 8400030
- Investigational Site Number 8400020
- Investigational Site Number 8400043
- Investigational Site Number 8400053
- Investigational Site Number 8400037
- Investigational Site Number 8400049
- Investigational Site Number 3480004
- Investigational Site Number 3480003
- Investigational Site Number 3480001
- Investigational Site Number 3480005
- Investigational Site Number 3480002
- Investigational Site Number 6160008
- Investigational Site Number 6160004
- Investigational Site Number 6160010
- Investigational Site Number 6160009
- Investigational Site Number 6160003
- Investigational Site Number 6160001
- Investigational Site Number 8040003
- Investigational Site Number 8040001
- Investigational Site Number 8040002
- Investigational Site Number 8040004
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Efpeglenatide 4 mg
Efpeglenatide 6 mg
Dulaglutide 1.5 mg
Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.